Skip to main content
Premium Trial:

Request an Annual Quote

Siemens Healthineers Gets FDA Premarket Approval for HCV Genotyping Test

NEW YORK (GenomeWeb) – Siemens Healthineers said today that the US Food and Drug Administration has granted the company a premarket approval for its Versant HCV Genotype 2.0 assay. According to the firm, the Versant test uses a single-step RT-PCR kit that can be run on commonly available thermocyclers. It identifies all six hepatitis C virus genotypes as well as subtypes 1a and 1b. Although effective HCV treatment regimens are available, they are not effective on all HCV genotypes. This means that determining genotype, as well as subtypes 1a or 1b, is important for planning patient therapy, Siemens explained. The assay provides flexible automation options to fit the needs and volume requirements of both small and large labs, the company added. "The FDA's approval of our Versant HCV [assay], along with last year's introduction of Versant kPCR sample prep at AACC, exemplifies Siemens Healthineers' commitment to — and excitement about — molecular diagnostics in the US,” Siemens Healthineers Head of molecular diagnostics Fernando Beils said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more